| 產(chǎn)品編號(hào) | BIO0963SM |
| 英文名稱 | Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab Biosimilar) |
| 別 名 | CTLA-4 / CD152 & B7-H1 / PD-L1 / CD274; Erfonrilimab |
| 抗體來(lái)源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 107.44kDa |
| 性 狀 | Lyophilized |
| 亞 型 | VHH-VHH-Fc |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Erfonrilimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Erfonrilimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 0.681 nM.
Erfonrilimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Erfonrilimab bound to huPD-L1-CHO-K cells, and the EC50 was 1.759 nM.
Erfonrilimab bound to huCTLA4-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Erfonrilimab bound to huCTLA4-CHO-K cells, and the EC50 was 14.510 nM.
Erfonrilimab bound to PD-L1 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Erfonrilimab bound in human PD-L1 Protein-His, and the EC50 was 0.012 nM.
Erfonrilimab bound to CTLA4 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Erfonrilimab bound in human CTLA4 Protein-His, and the EC50 was 0.010 nM.
The purity of Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) is 97.11%, determined by SEC-HPLC.
Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
